MedTrace Logo

Colchicine Use for Primary Prevention of Coronary Artery Disease

NCT05175274 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6792

Last updated 2022-03-21

No results posted yet for this study

Summary

Colchicine has been widely used as an anti-gout medicine in the past decades. Some recent clinical trials have proved that low-dose colchicine can be used as a secondary prevention drug for coronary artery disease because of its anti-inflammatory mechanism. However, the effect on primary prevention has not been observed sufficiently. The objective of this study is to determine whether colchicine reduces the incidence of CAD in patients and its safety for long-term use.

Conditions

Interventions

DRUG

Colchicine

Colchicine 0.5mg/tablet

DRUG

Placebo

matching placebo

Sponsors & Collaborators

  • Qingdao Municipal Hospital

    collaborator OTHER

  • Qingdao Central Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-06
Primary Completion
2027-03-01
Completion
2028-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05175274 on ClinicalTrials.gov